Finally, the Myc oncogene, a downstream target of PI3K/AKT pathway, commonly upregulated in many types of cancer [104], appears to act synergistically with AKT in the development of prostate tumorigenesis by altering, for instance, its sensitivity to mTOR inhibitors [105]. The gene discussed is AKT1; the disease is urogenital neoplasm.